
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
over 27 years ago
Participating Facultyover 27 years ago
Introductionover 27 years ago
Methotrexate Therapy in the Year 2000: Outstanding Questionsover 27 years ago
State-of-the-Art Combination Therapy in 1999over 27 years ago
Selected Abstractsover 27 years ago
CME Quizover 27 years ago
Bibliography





